In this week's edition...
— PIPC Comment to CMS on ICR Emphasizes QALY Transparency. See details below.
— The Wall Street Journal Details the Impact of Trump's Drug-Price Plan on the Disabled. Click here to read the article.
— NHC: Patients as Partners in Drug Pricing and Health System Reforms. View the statement here.
— The Wall Street Journal Discusses the Impact of Trump's MFN Policy. Click here to read the article.
— CMS Referenced QALYs in Explanations for Medicare Drug Price Negotiation Program. See details below.
— ACOG Releases Updated Prenatal Care Clinical Guidance. See details below.
— EACH/PIC Releases Results from Patient-Led Survey on Drug Affordability. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
-- Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
-- COGI Reiterates Process Concerns for Maryland PDAB, Highlights NAACP Resolution. Click here to view the letter.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.
— PIPC Comment to CMS on ICR Emphasizes QALY Transparency. See details below.
— The Wall Street Journal Details the Impact of Trump's Drug-Price Plan on the Disabled. Click here to read the article.
— NHC: Patients as Partners in Drug Pricing and Health System Reforms. View the statement here.
— The Wall Street Journal Discusses the Impact of Trump's MFN Policy. Click here to read the article.
— CMS Referenced QALYs in Explanations for Medicare Drug Price Negotiation Program. See details below.
— ACOG Releases Updated Prenatal Care Clinical Guidance. See details below.
— EACH/PIC Releases Results from Patient-Led Survey on Drug Affordability. See details below.
— Data Mine Blog Analyzes a New Study from OHE on International Reference to QALYs. See details below.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
-- Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
-- COGI Reiterates Process Concerns for Maryland PDAB, Highlights NAACP Resolution. Click here to view the letter.
— National Minority Quality Forum Issue Brief Details MFN Consequences. Click here to read the issue brief.
— Report: Foreign Countries Rely on Flawed and Outdated HTA or Value Assessment Methods. Click here to read the report.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.
